Figure_3.tif (145.52 kB)
Overall survival of patients who received bevacizumab after progression compared to those who didn’t.
figure
posted on 2013-08-05, 03:44 authored by Jennifer Ho, John Ondos, Holly Ning, Sharon Smith, Teri Kreisl, Fabio Iwamoto, Joohee Sul, Lyndon Kim, Kate McNeil, Andra Krauze, Uma Shankavaram, Howard A. Fine, Kevin CamphausenPatients receiving bevacizumab had a median OS of 23.3 months (95% CI: 17.1–35.6), compared to 16.3 months (95% CI: 13.8–25.1) in patients who did not receive it, P = 0.0284.
